false
OasisLMS
zh-CN,zh-TW,en,pt,es
Login
Catalog
Screening and Lifestyle Management of Liver Health ...
Screening and Lifestyle Management of Liver Health ...
Screening and Lifestyle Management of Liver Health: Incorporating Liver Health into Diabetes Self-Management Education and Support (DSMES)
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
This American Diabetes Association webinar focuses on screening and lifestyle management for liver health in diabetes care, emphasizing metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). The speaker explains that MASLD is strongly linked to metabolic syndrome—especially visceral/abdominal adiposity and insulin resistance—and is highly prevalent in type 2 diabetes (over 70%), with substantial progression risk to MASH and fibrosis. Because MASLD can advance from steatosis to fibrosis, cirrhosis, and liver cancer, early detection is critical.<br /><br />Updated ADA Standards of Care (2026) recommend risk stratification using the noninvasive Fibrosis-4 (FIB-4) Index (age, AST/ALT, platelets). Low scores suggest minimal fibrosis; higher scores prompt further assessment for liver stiffness (e.g., elastography, ELF testing) and possible referral.<br /><br />Lifestyle intervention is presented as the cornerstone of management: target 7–10% weight loss (greater losses improve MASH resolution and fibrosis regression), improve diet quality (limit saturated fat, refined carbs, added sugars/high-fructose corn syrup; increase fiber, whole foods), increase physical activity (aerobic plus resistance training), reduce/avoid alcohol, stop smoking, manage stress, and prioritize sleep. Mediterranean and DASH patterns have the strongest evidence; other patterns may help but need more data. Coffee (black) may be beneficial. Pharmacotherapy is emerging for F2–F3 fibrosis, alongside ongoing obesity/diabetes treatment, but options are limited in cirrhosis.
Keywords
American Diabetes Association webinar
MASLD
MASH
type 2 diabetes liver disease
FIB-4 Index screening
noninvasive fibrosis risk stratification
elastography and ELF testing
lifestyle intervention weight loss 7–10%
Mediterranean and DASH diet
×
Please select your language
1
English